X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nanoliposomal irinotecan (46) 46
pancreatic cancer (31) 31
gemcitabine (30) 30
oncology (29) 29
index medicus (27) 27
cancer (22) 22
chemotherapy (21) 21
humans (21) 21
irinotecan (20) 20
metastasis (17) 17
pancreatic neoplasms - drug therapy (17) 17
survival (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
folfirinox (14) 14
adenocarcinoma (13) 13
folinic acid (13) 13
nab-paclitaxel (13) 13
therapy (13) 13
camptothecin - analogs & derivatives (12) 12
pharmacology & pharmacy (12) 12
care and treatment (11) 11
randomized phase-ii (11) 11
5-fluorouracil (10) 10
animals (10) 10
clinical trials (10) 10
liposomes (10) 10
camptothecin - administration & dosage (9) 9
mm-398 (9) 9
oxaliplatin (9) 9
pancreatic neoplasms - pathology (9) 9
patients (9) 9
analysis (8) 8
liposomal irinotecan (8) 8
nanoparticles (8) 8
treatment outcome (8) 8
adenocarcinoma - drug therapy (7) 7
fluorouracil (7) 7
fluorouracil - administration & dosage (7) 7
metastases (7) 7
2nd-line chemotherapy (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
camptothecin - therapeutic use (6) 6
disease-free survival (6) 6
drug therapy (6) 6
female (6) 6
leucovorin - administration & dosage (6) 6
male (6) 6
nal-iri (6) 6
pancreatic neoplasms - mortality (6) 6
2nd-line therapy (5) 5
aged (5) 5
cancer therapies (5) 5
development and progression (5) 5
drug delivery systems (5) 5
medicine & public health (5) 5
oxaliplatin folfirinox (5) 5
pancreatic adenocarcinoma (5) 5
pep02 (5) 5
phase-iii trial (5) 5
tumor (5) 5
2nd-line treatment (4) 4
aged, 80 and over (4) 4
antineoplastic agents, phytogenic - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
article (4) 4
carcinoma, pancreatic ductal - drug therapy (4) 4
combination (4) 4
efficacy (4) 4
hematology (4) 4
medical prognosis (4) 4
mice (4) 4
middle aged (4) 4
napoli-1 (4) 4
neoplasm metastasis (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
paclitaxel plus gemcitabine (4) 4
pancreas (4) 4
randomized controlled trials as topic (4) 4
toxicity (4) 4
trial (4) 4
tumors (4) 4
adenocarcinoma - mortality (3) 3
adenocarcinoma - secondary (3) 3
adult (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antitumor-activity (3) 3
camptothecin - adverse effects (3) 3
camptothecin - pharmacokinetics (3) 3
cancer patients (3) 3
colorectal cancer (3) 3
colorectal-cancer (3) 3
confidence intervals (3) 3
deoxycytidine - analogs & derivatives (3) 3
deoxyribonucleic acid--dna (3) 3
digestive system diseases (3) 3
drug dosages (3) 3
drugs (3) 3
gastroenterology & hepatology (3) 3
health aspects (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Medicine, ISSN 2045-7634, 04/2016, Volume 5, Issue 4, pp. 676 - 683
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 50, pp. 142 - 147
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 03/2016, Volume 76, Issue 5, pp. 1066 - 1077
Journal Article
Journal Article
Journal of Geriatric Oncology, ISSN 1879-4068, 05/2019, Volume 10, Issue 3, pp. 427 - 435
Pancreatic cancer is a highly lethal disease predominantly affecting older patients. Characterization of outcomes in these patients may help optimise treatment... 
Older patients | Liposomal irinotecan | Pancreatic cancer | Nal-IRI | SURVIVAL | FOLFIRINOX | ADENOCARCINOMA | OXALIPLATIN | GEMCITABINE | CHEMOTHERAPY | NANOLIPOSOMAL IRINOTECAN | GERIATRICS & GERONTOLOGY | ONCOLOGY | RANDOMIZED PHASE-II | OUTCOMES | ELDERLY-PATIENTS | Aged patients | Usage | Metastasis | Drug therapy | Fluorouracil
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2017, Volume 79, Issue 3, pp. 603 - 610
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 07/2016, Volume 16, Issue 7, pp. 697 - 703
Journal Article
Expert Opinion on Orphan Drugs, ISSN 2167-8707, 05/2016, Volume 4, Issue 5, pp. 541 - 547
Introduction: Pancreatic cancer is a highly aggressive and lethal malignancy, with a particularly poor prognosis and limited treatment options, especially... 
Campothecins | MM-398 | pancreatic cancer | topoisomerase-I inhibitors | irinotecan hydrochloride | nanoliposomal irinotecan | FUTURE-DIRECTIONS | TUMOR | FOLINIC ACID | ANTITUMOR-ACTIVITY | GEMCITABINE | DELIVERY | CAMPTOTHECIN | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | PHASE-I
Journal Article
Medical Oncology, ISSN 1357-0560, 10/2019, Volume 36, Issue 10, pp. 1 - 8
The majority of pancreatic cancers are diagnosed at an advanced stage, when surgical options are limited and treatment relies on systemic chemotherapy. In the... 
Pathology | Nanoliposomal irinotecan | Metastatic pancreatic adenocarcinoma | Medicine & Public Health | Hematology | Oncology | Internal Medicine | FOLFIRI | Cost-effective | SURVIVAL | ONCOLOGY | NAB-PACLITAXEL | REGIMEN | GEMCITABINE | Antimitotic agents | Chemotherapy | Pancreatic cancer | Metastasis | Comparative analysis | Antineoplastic agents | Cancer
Journal Article
Future Oncology, ISSN 1479-6694, 02/2016, Volume 12, Issue 4, pp. 453 - 464
While progress in the treatment of advanced pancreatic cancer has accelerated in recent years, this malignancy continues to have an exceedingly poor prognosis,... 
MM-398 | pancreatic cancer | PEP02 | irinotecan | nanoliposomal | SURVIVAL | MECHANISM | 2ND-LINE CHEMOTHERAPY | PHASE-II | FAILURE | GEMCITABINE | ONCOLOGY | COLORECTAL-CANCER | PLUS NAB-PACLITAXEL | OXALIPLATIN FOLFIRINOX | Index Medicus
Journal Article